Sitagliptin in Recurrent/Progressive Grade 4 Glioma, Phase 1
ClinicalTrials.gov Studies
Summary
NIH has registered a Phase 1 clinical trial (NCT07541781) evaluating sitagliptin in combination with bevacizumab for the treatment of recurrent or progressive grade 4 malignant glioma. The trial is enrolling adult patients with glioblastoma or recurrent glioma and is expected to run through April 2026. The study aims to assess efficacy and determine the maximum appropriate dose of sitagliptin when combined with standard-of-care bevacizumab.
“Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.”
What changed
NIH has registered a Phase 1 clinical trial (NCT07541781) on ClinicalTrials.gov testing sitagliptin in combination with bevacizumab for recurrent or progressive grade 4 glioma. The trial enrolls adult patients diagnosed with glioblastoma or recurrent glioma and is listed as Phase 1 with an anticipated completion date of April 2026.
Healthcare providers, clinical investigators, and pharmaceutical companies involved in neuro-oncology research should be aware of this trial as it represents an active Phase 1 investigation combining a DPP-4 inhibitor with anti-VEGF therapy for a high-grade malignancy with limited treatment options. No compliance obligations or reporting requirements arise from this registration entry.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Phase 1 NCT07541781 Kind: PHASE1 Apr 21, 2026
Abstract
Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.
Conditions: Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)
Interventions: Sitagliptin, Bevacizumab
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.